FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170097756> ?p ?o ?g. }

• W3170097756 endingPage "S34" @default.
• W3170097756 startingPage "S34" @default.
• W3170097756 abstract "To determine the cost-effectiveness of XVd in previously treated MM. The phase III BOSTON trial of once weekly XVd versus twice weekly bortezomib and dexamethasone (Vd) was the basis for this cost-effectiveness analysis (CEA) from a US commercial payer perspective. Comparators to XVd included daratumumab/pomalidomide/dexamethasone (DPd), daratumumab/lenalidomide/dexamethasone (DRd), lenalidomide/dexamethasone (Rd), pomalidomide/bortezomib/dexamethasone (PVd), elotuzumab/pomalidomide/dexamethasone (EPd), carfilzomib/pomalidomide/dexamethasone (KPd), and daratumumab/bortezomib/dexamethasone (DVd). A partitioned survival model enabled the use of direct overall survival (OS) and progression-free survival (PFS) curves from BOSTON to generate four health states for XVd and Vd: PFS on treatment, PFS off treatment, post-progression, and mortality. Using a one-week cycle length, benefits and costs were discounted at 3.0% annually. Cost inputs included primary therapy and administration, secondary therapy, routine medical care, treatment-related adverse events, and mortality. Utility values were obtained from the literature using EQ-5D-5L data. Clinical outcomes for the comparators were based on results from a network meta-analysis. For XVd versus Vd, the base case incremental cost (Δ cost) was $158,368 and the base case incremental cost-effectiveness ratio (ICER) was $471,886/quality-adjusted life year (QALY). The 50% cost-effectiveness probability midpoint was near $470,000/QALY, based on probabilistic sensitivity analysis. XVd showed a higher QALY gain with a lower cost (i.e. was dominant) compared with Rd (Δ cost: $-41,693; ICER: $-70,606/QALY), PVd (Δ cost: $-79,453; ICER: $-5,154,447/QALY), and KPd (Δ cost: $-81,834; ICER: $-59,269/QALY). XVd had lower cost and lower benefit compared with DPd (Δ cost: $-417,591; ICER: $147,482/QALY), DRd (Δ cost: $-974,308; ICER: $345,974/QALY), EPd (Δ cost: $-272,189; ICER: $465,716/QALY), and DVd (Δ cost: $-59,894; ICER: $11,367/QALY). The addition of XVd to the previously treated MM triplet regimen landscape provides a novel, oral treatment option that either was cost-effective (versus Vd, DPd, and DVd) at a willingness-to-pay threshold of $150,000, or dominant (versus Rd, PVd, and KPd)." @default.
• W3170097756 created "2021-06-22" @default.
• W3170097756 creator A5057254568 @default.
• W3170097756 creator A5061613530 @default.
• W3170097756 creator A5086846495 @default.
• W3170097756 date "2021-06-01" @default.
• W3170097756 modified "2023-09-27" @default.
• W3170097756 title "PCN82 Cost-Effectiveness of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM)" @default.
• W3170097756 doi "https://doi.org/10.1016/j.jval.2021.04.174" @default.
• W3170097756 hasPublicationYear "2021" @default.
• W3170097756 type Work @default.
• W3170097756 sameAs 3170097756 @default.
• W3170097756 citedByCount "1" @default.
• W3170097756 countsByYear W31700977562021 @default.
• W3170097756 crossrefType "journal-article" @default.
• W3170097756 hasAuthorship W3170097756A5057254568 @default.
• W3170097756 hasAuthorship W3170097756A5061613530 @default.
• W3170097756 hasAuthorship W3170097756A5086846495 @default.
• W3170097756 hasBestOaLocation W31700977561 @default.
• W3170097756 hasConcept C112930515 @default.
• W3170097756 hasConcept C126322002 @default.
• W3170097756 hasConcept C143998085 @default.
• W3170097756 hasConcept C2776063141 @default.
• W3170097756 hasConcept C2776364478 @default.
• W3170097756 hasConcept C2777478702 @default.
• W3170097756 hasConcept C2778524551 @default.
• W3170097756 hasConcept C2780401358 @default.
• W3170097756 hasConcept C2781119759 @default.
• W3170097756 hasConcept C3019080777 @default.
• W3170097756 hasConcept C71924100 @default.
• W3170097756 hasConceptScore W3170097756C112930515 @default.
• W3170097756 hasConceptScore W3170097756C126322002 @default.
• W3170097756 hasConceptScore W3170097756C143998085 @default.
• W3170097756 hasConceptScore W3170097756C2776063141 @default.
• W3170097756 hasConceptScore W3170097756C2776364478 @default.
• W3170097756 hasConceptScore W3170097756C2777478702 @default.
• W3170097756 hasConceptScore W3170097756C2778524551 @default.
• W3170097756 hasConceptScore W3170097756C2780401358 @default.
• W3170097756 hasConceptScore W3170097756C2781119759 @default.
• W3170097756 hasConceptScore W3170097756C3019080777 @default.
• W3170097756 hasConceptScore W3170097756C71924100 @default.
• W3170097756 hasLocation W31700977561 @default.
• W3170097756 hasOpenAccess W3170097756 @default.
• W3170097756 hasPrimaryLocation W31700977561 @default.
• W3170097756 hasRelatedWork W1197848312 @default.
• W3170097756 hasRelatedWork W2123159083 @default.
• W3170097756 hasRelatedWork W2478188943 @default.
• W3170097756 hasRelatedWork W2608137803 @default.
• W3170097756 hasRelatedWork W2905841490 @default.
• W3170097756 hasRelatedWork W2939294425 @default.
• W3170097756 hasRelatedWork W2980591007 @default.
• W3170097756 hasRelatedWork W3114717300 @default.
• W3170097756 hasRelatedWork W3167371147 @default.
• W3170097756 hasRelatedWork W4310120201 @default.
• W3170097756 hasVolume "24" @default.
• W3170097756 isParatext "false" @default.
• W3170097756 isRetracted "false" @default.
• W3170097756 magId "3170097756" @default.
• W3170097756 workType "article" @default.